Epidemiologie - France Portal | Health Databases

Home

Catalogue

Catalogue
ARCHIVES

Covid-19

Resources

Lexicon
Legal notices

Useful links

General links
Covid-19 links

Login in to your account

Email address Password

You do not have an account yet ? Sign up !

You have forgotten your password ?

Portail Epidémiologique

ITMO public health Aviesan

Aviesan

Archives

Search with one or more keywords

All records French records only English records only

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml

Export to XML

Please choose the format :

pdf

Export to PDF

Which version do you want to export ?

Download full content

Download light content

csv

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

CEREPHY - Brain Tumours and Plant Protection Products

Head : Salamon Roger, INSERM U 897
Baldi Isabelle

Version 1

139

Last update : 09/05/2017

ARCHIVE

CEREPHY - Brain Tumours and Plant Protection Products

Head : Salamon Roger, INSERM U 897
Baldi Isabelle

Main objective

To investigate the relationship between exposure to pesticides and central nervous system disorders (brain and spinal cord)

Inclusion criteria

Adults aged 16 years or more living in Gironde who have malignant or benign primitive brain tumours that were diagnosed between 1st May 1999 and 30th April 2001. Recurrence, secondary tumours, pituitary adenomas, asymptomatic tumours, incidentally discovered and vascular malformations were excluded from the study.

Last update : 09/05/2017

EULEV - Effectiveness and Use of Levetiracetam in Real Life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 3

140

Last update : 10/26/2017

ARCHIVE

EULEV - Effectiveness and Use of Levetiracetam in Real Life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The objectives of this study were to describe patients initiating treatment with levetiracetam, the prescribing patterns, and to evaluate the effectiveness of levetiracetam in a real-life situation in terms of treatment retention over one year.

Inclusion criteria

Patients who initiated treatment with levetiracetam between 01/01/2005 and 31/08/2005 or between 01/01/2006 and 31/08/2006 (irrespective of whether or not treatment was continued), and having never previously been treated with levetiracetam; patient agreeing to participate; patient can be followed over the next 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).

Last update : 10/26/2017

EULEVp - Effectiveness and Use of Levetiracetam of pediatrics in real life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 2

141

Last update : 10/26/2017

ARCHIVE

EULEVp - Effectiveness and Use of Levetiracetam of pediatrics in real life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The objectives of this study were to describe the children initiating treatment with levetiracetam, the prescribing patterns, and to evaluate the effectiveness of levetiracetam in a real situation in terms of treatment retention for one year.

Inclusion criteria

Patient aged under 16 years; Obtainment of consent from the guardian of the child; patient having initiated treatment with levetiracetam between 01/10/2006 and 31/03/2007 (whether or not the treatment was continued), and having never been previously treated with levetiracetam; patient who may be followed over the following 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).

Last update : 10/26/2017

EXTRA - Observatoire sur la fréquence des manifestations EXTRA-articulaires et plus particulièrement de l'uvéite chez les patients présentant une spondylarthropathie et suivis en consultation de rhumatologie

Head : Thibout Emmanuel

Version 2

142

Last update : 01/01/2020

ARCHIVE

EXTRA - Observatoire sur la fréquence des manifestations EXTRA-articulaires et plus particulièrement de l'uvéite chez les patients présentant une spondylarthropathie et suivis en consultation de rhumatologie

Head : Thibout Emmanuel

Main objective

Evaluation of the frequency of extra-articular manifestations and more specifically of uveitis in patients with a spondylarthropathy

Inclusion criteria

Patients suffering from a spondylarthropathy

Last update : 01/01/2020

POSTEPI - Management of osteoporosis and associated quality of life in post menopausal women

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1

143

Last update : 01/01/2018

ARCHIVE

POSTEPI - Management of osteoporosis and associated quality of life in post menopausal women

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

In the framework of the new screening and reimbursement conditions for osteoporosis medications, describe the profile of postmenopausal women with osteoporosis and treated for less than 6 months

Inclusion criteria

Postmenopausal women diagnosed with osteoporosis less than 6 months ago via low BMD (Femoral total T score and/or spinal average <-2.5) or on a fracture not linked to a major trauma or to a cancer and treated for less than 6 months

Last update : 01/01/2018

SMP: prevalence study - Cross-sectional study of the mental health of prisoners: prevalence study

Head : Falissard Bruno, Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Reynaud Michel

Version 1

144

Last update : 10/20/2017

ARCHIVE

SMP: prevalence study - Cross-sectional study of the mental health of prisoners: prevalence study

Head : Falissard Bruno, Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Reynaud Michel

Main objective

To calculate the prevalence of psychiatric disorders in the prison environment

Inclusion criteria

Prisoners (male and female) in institutions selected randomly in the protocol

Last update : 10/20/2017

Previous
1
...
18
19
20
21
22
23
24
25
26
27
28
29
30
...
52
Next

Please wait...

ABOUT

Help about your workspace

CATALOG

RESOURCES

USEFUL LINKS

This site complies with the HONcode standard for trustworthy health information:
verify here.

8 rue de la Croix Jarry

75013 Paris

Phone : +33 1 44 23 67 47

portail-epidemiologie@inserm.fr

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

XXX

View Edit Create here